Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

The number needed to treat for second-generation biologics when treating established rheumatoid arthritis: a systematic quantitative review of randomized controlled trials.

Kristensen LE, Jakobsen AK, Bartels EM, Geborek P, Bliddal H, Saxne T, Danneskiold-Samsøe B, Christensen R.

Scand J Rheumatol. 2011 Jan;40(1):1-7. doi: 10.3109/03009742.2010.491834. Epub 2010 Oct 15. Review.

PMID:
20950126
2.

Efficacy of methotrexate in comparison to biologics in rheumatoid arthritis.

Rau R.

Clin Exp Rheumatol. 2010 Sep-Oct;28(5 Suppl 61):S58-64. Epub 2010 Oct 28. Review. Erratum in: Clin Exp Rheumatol. 2011 Mar-Apr;29(2):364.

PMID:
21044435
3.

Tocilizumab for rheumatoid arthritis: a Cochrane systematic review.

Singh JA, Beg S, Lopez-Olivo MA.

J Rheumatol. 2011 Jan;38(1):10-20. doi: 10.3899/jrheum.100717. Epub 2010 Oct 15. Review.

PMID:
20952462
4.

Golimumab for rheumatoid arthritis: a systematic review.

Singh JA, Noorbaloochi S, Singh G.

J Rheumatol. 2010 Jun;37(6):1096-104. doi: 10.3899/jrheum.091466. Epub 2010 May 1. Review.

PMID:
20436075
5.

Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage.

[No authors listed]

Prescrire Int. 2009 Oct;18(103):198-201.

PMID:
19882783
6.

Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.

Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, Han J, Taylor P.

Arthritis Rheum. 2010 Apr;62(4):917-28. doi: 10.1002/art.27348. Erratum in: Arthritis Rheum. 2010 Oct;62(10):3130.

7.

Comparative overview of safety of the biologics in rheumatoid arthritis.

Khraishi M.

J Rheumatol Suppl. 2009 Jun;82:25-32. doi: 10.3899/jrheum.090128. Review.

PMID:
19509327
8.

Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs.

Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP.

Semin Arthritis Rheum. 2010 Jun;39(6):425-41. doi: 10.1016/j.semarthrit.2009.12.002. Epub 2010 Mar 11. Review.

PMID:
20223500
9.

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.

Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z, Visvanathan S, Rahman MU.

Arthritis Rheum. 2008 Apr;58(4):964-75. doi: 10.1002/art.23383. Erratum in: Arthritis Rheum. 2010 Nov;62(11):3518.

10.

Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate.

Pierreisnard A, Issa N, Barnetche T, Richez C, Schaeverbeke T.

Joint Bone Spine. 2013 Jul;80(4):386-92. doi: 10.1016/j.jbspin.2012.09.023. Epub 2012 Nov 7. Review.

PMID:
23141718
11.
12.

Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.

Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO 3rd, Bathon J.

Semin Arthritis Rheum. 2009 Oct;39(2):123-31. doi: 10.1016/j.semarthrit.2008.08.002. Epub 2008 Sep 27. Review.

PMID:
18823645
13.
14.

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate.

Maini RN, Taylor PC, Szechinski J, Pavelka K, Bröll J, Balint G, Emery P, Raemen F, Petersen J, Smolen J, Thomson D, Kishimoto T; CHARISMA Study Group.

Arthritis Rheum. 2006 Sep;54(9):2817-29. Erratum in: Arthritis Rheum. 2008 Mar;58(3):887.

15.

Examining the efficacy of biologic therapy: are there real differences?

Fleischmann RM.

J Rheumatol Suppl. 2002 Sep;65:27-32. Review.

PMID:
12236619
16.

Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.

Zintzaras E, Dahabreh IJ, Giannouli S, Voulgarelis M, Moutsopoulos HM.

Clin Ther. 2008 Nov;30(11):1939-55. doi: 10.1016/j.clinthera.2008.11.007. Review.

PMID:
19108784
17.

Number needed to treat (NNT): implication in rheumatology clinical practice.

Osiri M, Suarez-Almazor ME, Wells GA, Robinson V, Tugwell P.

Ann Rheum Dis. 2003 Apr;62(4):316-21.

18.

The use of biologic therapies in the treatment of rheumatoid arthritis.

Wang D, Li Y, Liu Y, Shi G.

Curr Pharm Biotechnol. 2014;15(6):542-8. Review.

PMID:
25213363
19.

Incomplete reporting of recruitment information in clinical trials of biologic agents for the treatment of rheumatoid arthritis: a review.

Simsek I, Yazici Y.

Arthritis Care Res (Hoboken). 2012 Oct;64(10):1611-6. doi: 10.1002/acr.21721. Review.

20.

Rituximab treatment of refractory rheumatoid arthritis.

Summers KM, Kockler DR.

Ann Pharmacother. 2005 Dec;39(12):2091-5. Epub 2005 Oct 25. Review.

PMID:
16249269
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk